This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Retinoids in treatment of psoriasis

Authoring team

Topical retinoid treatment:

  • tazarotene (available in 0.05% & 0.1% gels or creams) is a topical retinoid licensed for the treatment of psoriasis
  • it has a relatively low efficacy
  • may cause soreness and burning
  • should not be used in pregnancy
  • as with other topical therapies, combination therapy has been tried, eg combining tazarotene with a topical corticosteroid increased efficacy while reducing the incidence of local adverse effects (1)

Oral retinoid therapy:

  • Requires dermatologist supervision
    • Acitretin is an effective oral retinoid as a monotherapy
    • long term therapy may be necessary since retinoids only suppresses the disease process
    • retinoids are potent antipsoriatic drugs for pustular and erythrodermic psoriasis but are less effective in chronic plaque psoriasis
    • when used in combination with PUVA it has been shown to reduce the required dosage (both UVA and acitretin) to achieve clearance
    • side effects - drying and cracking of lips, dryness of the nasal buccal and conjunctival mucosa, elevation of liver enzymes (20-30%) and plasma lipid levels (up to 25%)
    • due to the teratogenicity of the drug it should be avoided in pregnancy and patients should be advised not to get pregnant for a period of 2 years after stopping acitretin (3)

Consult the summary of product characteristics before prescribing this drug.

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.